GlassScriptPhysician profile
Jason Michael Machado
NPI 1225732845
$5,523.98
in general payments reported to CMS, 2019-2025
23 companies · $3,157 in 2025
The $3,157 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $367 · 2024: $2,000 · 2025: $3,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,523.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $1,653.77 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $886.96 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Infinion 16 |
| Nevro Corp. | $488.19 | 2023-2024 | Senza |
| Medtronic, INC. | $470.35 | 2024 | Synchromedii, Intellis Adaptivestim, Venaseal |
| Globus Medical, INC. | $359.88 | 2025 | Senza, Vyrsa V1 |
| Vertex Pharmaceuticals Incorporated | $284.68 | 2025 | |
| Si-Bone, INC. | $224.13 | 2024-2025 | |
| Pfizer INC. | $177.42 | 2023-2025 | |
| Vertos Medical, INC. | $167.49 | 2023-2024 | Mild Device Kit |
| Biotronik Nro, INC. | $166.25 | 2025 | Prospera |
| Bioventus LLC | $150.53 | 2023-2025 | Durolane, Durolane, Gelsyn-3 |
| Abbvie INC. | $132.03 | 2023-2025 | |
| Curonix LLC | $102.97 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Painteq LLC | $49.81 | 2024 | Painteq |
| Merz Pharmaceuticals, LLC | $39.38 | 2024 | Xeomin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $26.88 | 2025 | Zilretta, Iovera |
| Nalu Medical, INC. | $26.53 | 2025 | Nalu Neurostimulation System |
| Lundbeck LLC | $25.28 | 2023 | Abilify Asimtufii |
| Spinal Simplicity, LLC | $20.07 | 2025 | Ha Minuteman G3-R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.50 | 2024 | Relistor |
| Horizon Therapeutics Plc | $18.21 | 2023 | Krystexxa |
| Stryker Corporation | $18.06 | 2024 | Omnicurve |
| Idorsia Pharmaceuticals US INC | $15.61 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Machado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.